Brief: Athira Pharma Reports Results From Phase 2 Study Of Alzheimer's Disease Treatment

LeonaBio

22/06/2022 12:19

June 22 (Reuters) - Athira Pharma Inc  ATHA.O :
    * ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE
2
PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE
ALZHEIMER’S DISEASE
    * ATHIRA PHARMA INC - PRIMARY ENDPOINT OF CHANGE IN
BIOMARKER ERP
P300 LATENCY WAS NOT STATISTICALLY SIGNIFICANT FOR FULL STUDY
POPULATION
    * ATHIRA PHARMA INC - COMBINATION OF FOSGONIMETON AND
STANDARD-OF-CARE (ACHEIS) GIVEN TOGETHER SHOWED POTENTIAL
DIMINISHED EFFECT OF FOSGONIMETON
    * ATHIRA PHARMA INC - FOSGONIMETON HAD A FAVORABLE SAFETY
PROFILE
OVER 26 WEEKS AND ACT-AD PROVIDES IMPORTANT LEARNINGS FOR
ONGOING LIFT-AD STUDY
    * ATHIRA PHARMA INC - A PRE-SPECIFIED SUBGROUP ANALYSIS OF
PATIENTS ON FOSGONIMETON MONOTHERAPY SUGGESTS IMPROVEMENT IN ERP
P300 LATENCY AT WEEK 26
    * ATHIRA PHARMA INC - A PRE-SPECIFIED SUBGROUP ANALYSIS OF
PATIENTS ON FOSGONIMETON MONOTHERAPY SUGGESTS IMPROVEMENT IN
ADAS-COG11 AT WEEK 26

Source text for Eikon:  ID:nGNX68F5qR 
Further company coverage:  ATHA.O 

 ((Reuters.Briefs@thomsonreuters.com;))